NCT05805371
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Nov 11, 2028 to Nov 11, 2029 Show 4 more changesShow less
- Eligibility criteria expanded, about 21 words
- Interventions: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (Biological), Biopsy (Procedure), Biospecimen Collection (Procedure)… to Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (Biological), Biopsy (Procedure), Biospecimen Collection (Procedure)…
- Secondary endpoints: details revised at 2 of 9 entries
- Study description revised
- Notable Start date: Jul 19, 2024 to Oct 9, 2024v13
- Notable Primary and study completion dates: Nov 11, 2026 to Nov 11, 2028v12
- Minor Start date changed from estimate of Nov 1, 2024 to Jul 19, 2024v11
- Notable Start date: Sep 1, 2024 to Nov 1, 2024
- Primary and study completion dates moved earlier to Nov 11, 2026
Show 8 earlier versionsHide 8 earlier versions
- Notable Start date: Jun 12, 2024 to Sep 1, 2024v9
- Notable Start date: Apr 12, 2024 to Jun 12, 2024v8
- Notable Start date: Feb 12, 2024 to Apr 12, 2024v7
- Notable Primary completion date: Nov 9, 2025 to Aug 1, 2027
- Start date: Dec 30, 2023 to Feb 12, 2024
- Study completion date: Nov 9, 2025 to Jul 1, 2028
- Notable Start date: Oct 30, 2023 to Dec 30, 2023
- Primary and study completion dates: Feb 26, 2026 to Nov 9, 2025
- Notable Start date: Jul 30, 2023 to Oct 30, 2023v4
- Notable Start date: May 30, 2023 to Jul 30, 2023v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Sep 7, 2023 to May 30, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Patients undergo leukapheresis and lymphodepletion and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
Patients undergo leukapheresis, radiation in 2 doses, and lymphodepletion, and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
Biologicals: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Procedures: Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lymphodepletion Therapy
Radiation: External Beam Radiation Therapy
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States